ERBB2 and breast cancer: Indeed, in a recent study that was conducted in immunocompetent mouse models of HER2+ solid tumors (including BC), a combination of anti-PD-1 with HER2 CAR-M cell therapy demonstrated better OS and tumor control than monotherapy strategies [78].